BACKGROUND AND OBJECTIVES:MHAA4549A, a human anti-influenza immunoglobulin (Ig) G1 monoclonal antibody, is being developed to treat patients hospitalized for influenza A infection. This study examined the pharmacokinetics (PKs) of MHAA4549A in a phase IIa, randomized, double-blind, dose-ranging trial in healthy volunteers challenged with influenza A virus. METHODS:Serum PK data were collected from 60 subjects in three single-dose groups (400, 1200, or 3600 mg) who received MHAA4549A intravenously 24-36 h after inoculation with the influenza A virus. Nasopharyngeal swab MHAA4549A concentration data were collected on days 1-8, and all subjects, including the placebo group, received 75 mg oseltamivir twice daily from days 7 to 11. Plasma samples were collected 4 h postdose on day 8 for oseltamivir and its active metabolite oseltamivir carboxylate (OC) (all subjects, n = 100), including subjects treated with oseltamivir alone and placebo. Noncompartmental analysis was performed for both nasal and serum PKs. RESULTS:MHAA4549A showed dose-proportional serum PKs with a long terminal half-life (approximately 21.9-24.6 days) and slow clearance (approximately 152-240 mL/day); however, nasopharyngeal swab PKs were not dose proportional. No differences in mean plasma concentrations of oseltamivir and OC at 4 h postdose on day 8 were observed between the MHAA4549A treatment and placebo groups. No subjects who received MHAA4549A developed anti-drug antibodies. CONCLUSION:MHAA4549A serum PKs were consistent with that of a human IgG1antibody without known endogenous targets. MHAA4549A showed nonlinear PKs in nasopharyngeal swab samples, which will guide future dose selection to achieve the high drug concentrations needed at the site of action for efficacy. These data demonstrate no PK interactions between MHAA4549A and oseltamivir, and support flat dosing. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01980966.
RCT Entities:
BACKGROUND AND OBJECTIVES:MHAA4549A, a human anti-influenza immunoglobulin (Ig) G1 monoclonal antibody, is being developed to treat patients hospitalized for influenza A infection. This study examined the pharmacokinetics (PKs) of MHAA4549A in a phase IIa, randomized, double-blind, dose-ranging trial in healthy volunteers challenged with influenza A virus. METHODS: Serum PK data were collected from 60 subjects in three single-dose groups (400, 1200, or 3600 mg) who received MHAA4549A intravenously 24-36 h after inoculation with the influenza A virus. Nasopharyngeal swab MHAA4549A concentration data were collected on days 1-8, and all subjects, including the placebo group, received 75 mg oseltamivir twice daily from days 7 to 11. Plasma samples were collected 4 h postdose on day 8 for oseltamivir and its active metabolite oseltamivir carboxylate (OC) (all subjects, n = 100), including subjects treated with oseltamivir alone and placebo. Noncompartmental analysis was performed for both nasal and serum PKs. RESULTS:MHAA4549A showed dose-proportional serum PKs with a long terminal half-life (approximately 21.9-24.6 days) and slow clearance (approximately 152-240 mL/day); however, nasopharyngeal swab PKs were not dose proportional. No differences in mean plasma concentrations of oseltamivir and OC at 4 h postdose on day 8 were observed between the MHAA4549A treatment and placebo groups. No subjects who received MHAA4549A developed anti-drug antibodies. CONCLUSION:MHAA4549A serum PKs were consistent with that of a human IgG1antibody without known endogenous targets. MHAA4549A showed nonlinear PKs in nasopharyngeal swab samples, which will guide future dose selection to achieve the high drug concentrations needed at the site of action for efficacy. These data demonstrate no PK interactions between MHAA4549A and oseltamivir, and support flat dosing. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01980966.
Authors: Shuang Bai; Karin Jorga; Yan Xin; Denise Jin; Yanan Zheng; Lisa A Damico-Beyer; Manish Gupta; Meina Tang; David E Allison; Dan Lu; Yi Zhang; Amita Joshi; Mark J Dresser Journal: Clin Pharmacokinet Date: 2012-02-01 Impact factor: 6.447
Authors: A S Monto; D M Fleming; D Henry; R de Groot; M Makela; T Klein; M Elliott; O N Keene; C Y Man Journal: J Infect Dis Date: 1999-08 Impact factor: 5.226
Authors: Ning Chai; Lee R Swem; Mike Reichelt; Haiyin Chen-Harris; Elizabeth Luis; Summer Park; Ashley Fouts; Patrick Lupardus; Thomas D Wu; Olga Li; Jacqueline McBride; Michael Lawrence; Min Xu; Man-Wah Tan Journal: PLoS Pathog Date: 2016-06-28 Impact factor: 6.823
Authors: Jacqueline M McBride; Jeremy J Lim; Tracy Burgess; Rong Deng; Michael A Derby; Mauricio Maia; Priscilla Horn; Omer Siddiqui; Daniel Sheinson; Haiyin Chen-Harris; Elizabeth M Newton; Dimitri Fillos; Denise Nazzal; Carrie M Rosenberger; Maikke B Ohlson; Rob Lambkin-Williams; Hosnieh Fathi; Jeffrey M Harris; Jorge A Tavel Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee Journal: Antiviral Res Date: 2017-11-21 Impact factor: 5.970
Authors: S Omar Ali; Therese Takas; Andrew Nyborg; Kathryn Shoemaker; Nicole L Kallewaard; Rafael Chiong; Filip Dubovsky; Raburn M Mallory Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: Adam McNee; Trevor R F Smith; Barbara Holzer; Becky Clark; Emily Bessell; Ghiabe Guibinga; Heather Brown; Katherine Schultheis; Paul Fisher; Stephanie Ramos; Alejandro Nunez; Matthieu Bernard; Simon Graham; Veronica Martini; Tiphany Chrun; Yongli Xiao; John C Kash; Jeffery K Taubenberger; Sarah Elliott; Ami Patel; Peter Beverley; Pramila Rijal; David B Weiner; Alain Townsend; Kate E Broderick; Elma Tchilian Journal: J Immunol Date: 2020-06-26 Impact factor: 5.422
Authors: Rong Deng; Gaohong She; Mauricio Maia; Jeremy J Lim; Melicent C Peck; Jacqueline M McBride; Priya Kulkarni; Priscilla Horn; Aide Castro; Elizabeth Newton; Jorge A Tavel; William D Hanley Journal: J Clin Pharmacol Date: 2020-07-04 Impact factor: 3.126
Authors: Barbara Holzer; Pramila Rijal; Adam McNee; Basudev Paudyal; Veronica Martini; Becky Clark; Tanuja Manjegowda; Francisco J Salguero; Emily Bessell; John C Schwartz; Katy Moffat; Miriam Pedrera; Simon P Graham; Alistair Noble; Marie Bonnet-Di Placido; Roberto M La Ragione; William Mwangi; Peter Beverley; John W McCauley; Rodney S Daniels; John A Hammond; Alain R Townsend; Elma Tchilian Journal: PLoS Pathog Date: 2021-03-04 Impact factor: 6.823
Authors: Jeremy J Lim; Sadia Dar; Dirk Venter; Juan P Horcajada; Priya Kulkarni; Allen Nguyen; Jacqueline M McBride; Rong Deng; Joshua Galanter; Tom Chu; Elizabeth M Newton; Jorge A Tavel; Melicent C Peck Journal: Open Forum Infect Dis Date: 2021-12-10 Impact factor: 3.835